Regression of hepatocellular carcinoma and increase overall survival in patients treated with ledipasvir/sofosbuvir for hepatitis C virus infection: real-life single-center experience

Levan Gogichaishvili, Gia Lobzhanidze, Nana Goishvili, Mikheil Jangavadze



Background: Chronic hepatitis C induced liver cirrhosis is one of the main causes of the Hepatocellular carcinoma (HCC). There are controversial data about the effects of the different anti-hepatitis C virus treatment regiments on the risk of development and prognosis of HCC.  Furthermore, there is not any data about HCC prognosis in patients who undergoes viral eradication therapy. Recently, “Nationwide hepatitis C elimination program” was launched in Georgia. According to the protocol, patients with HCC also are included in the program.

Aim: The goal of the study was to determine the effect of the Ledipasvir/Sofosbuvir on HCCregression, disease free and Overall Survivals in Patients with Hepatitis C Virus

Methods: Patients were enrolled in a period of January – December 2015 year (n=6). Inclusion criteria – diagnosis of HCC or HCC recurrence and HCV-related cirrhosis who had been selected for surgical resection at the beginning of Led/Sof therapy. Clinical monitoring and management of adverse events were performed at a regular base.

Results: Our data show that in the treatment group early phase (12 months) intrahepatic recurrence rate is less than in control data, but without statistical significance (40% versus 50%, p=0.747). Improvement of late survival (maximum observation time 36 month) is more evident - (40% versus 50%, p=0.12), but still failed to reach statistical significance.

Overall survival was significantly higher. In the treatment group mean overall survival was 34.0±2.0 month in comparison with the control group - 25.2±3.6, P<0.05.  In one case regression of the size of the recurred tumour were observed.

Conclusions: Antiviral treatment can be included in the management of HCV patients with HCC. It may have additional benefits, in terms of improvement of overall and recurrence-free survival in cancer patients. Antiviral treatment could be indicated in the subgroup of patients with HCV-pure infection in whom recurrences can be significantly reduced. Also considering that our investigation is based on a small group of the patients, Further study on should be made in larger cohorts. Also, it will be valuable to explain mechanisms of the effect of the Ledipasvir/sofosbuvir on cancer regression.



Harvoni; Hepatocellular carcinoma (HCC); Hepatitis C virus (HCV); Tumour regression; Survival;

Full Text:



The A. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. Journal of Hepatology. 2016;65(4):734-740.

Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. Mar 05 2013;158(5 Pt 1):329-337.

D'Ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? Liver Int. Jun 2016;36(6):783-790.

van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. Dec 26 2012;308(24):2584-2593.

Lee HJ, Yeon JE, Yoon EL, et al. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years. Intervirology. 2015;58(1):14-21.

Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. Oct 2016;65(4):663-665.

Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. Oct 2016;65(4):719-726.

Huang JF, Yeh ML, Yu ML, et al. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol. Dec 2015;30(12):1768-1774.

Buonfiglioli F, Conti F, Andreone P, et al. Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals. Journal of Hepatology.64(2):S215.

Gvinjilia L. National Progress Toward Hepatitis C Elimination—Georgia, 2015–2016. MMWR. Morbidity and Mortality Weekly Report. 2016;65.

Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a nationwide hepatitis C elimination program—Georgia, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64(28):753-757.

Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. Feb 2003;38(2):200-207.

Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. Dec 2006;44(6):1543-1554.

Lencioni R, Montal R, Torres F, et al. Objective Response by mRECIST as a Predictor and Potential Surrogate End Point of Overall Survival in Advanced HCC. J Hepatol. Jan 25 2017.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. Sep 22 2011;365(12):1118-1127.

Liver EAFTSOT. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 2012;56(4):908-943.

Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. May 18 2002;359(9319):1734-1739.

Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. Oct 01 2013;31(28):3509-3516.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. Jul 24 2008;359(4):378-390.

Chang WY. Complete spontaneous regression of cancer: four case reports, review of literature, and discussion of possible mechanisms involved. Hawaii Med J. Oct 2000;59(10):379-387.

Everson TC, Cole WH. Spontaneous regression of cancer: a study and abstract of reports in the world medical literature and of personal communications concerning spontaneous regression of malignant disease: Saunders (WB) Co Ltd; 1966.

Levy C. Spontaneous Regression of Hepatocellular Carcinoma after Eradication of HCV. Journal of Gastroenterology, Pancreatology & Liver Disorders. 2014;1(4).

Mahmood S, Gul A, Saif T. Regression of hepatocellular carcinoma after treatment with Sofosbuvir - A case report. J Pak Med Assoc. Nov 2016;66(11):1507-1509.

Verla-Tebit E, Rahma OE. Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report. J Gastrointest Oncol. Jun 2015;6(3):E52-54.

Lim DH, Park KW, Lee SI. Spontaneous complete regression of multiple metastases of hepatocellular carcinoma: A case report. Oncol Lett. Apr 2014;7(4):1225-1228.

Bastawrous S, Kogut MJ, Bhargava P. Spontaneous regression of hepatocellular carcinoma in a cirrhotic patient: possible vascular hypothesis. Singapore Med J. Oct 2012;53(10):e218-221.

Zhou L, Fu JL, Lu YY, et al. Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol. Sep 2010;45(9):968-978.

Oquinena S, Guillen-Grima F, Inarrairaegui M, Zozaya JM, Sangro B. Spontaneous regression of hepatocellular carcinoma: a systematic review. Eur J Gastroenterol Hepatol. Mar 2009;21(3):254-257.

Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB (Oxford). Aug 2012;14(8):500-505.

Ogawa E, Iio E, Won Jun D, al. E. Effectiveness and Safety of DAA Treatment for Chronic Hepatitis C Patients with Previous Hepatocellular Carcinoma: Results from a Real‐World, Multicenter Study of Asian Countries. AASLD annual meeting Vol I. San Francisco, USA; 2018:34A.



  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)